Mesa Laboratories Earnings Call Transcripts
Fiscal Year 2027
-
Q2 organic growth accelerated to 2.6%, while Adjusted EBITDA rose 21.1%. FY27 guidance targets 5%-8% Adjusted EBITDA growth, supported by cost actions and disciplined capital allocation, though SDC delivery and Clinical Genomics restructuring remain key execution issues.
-
Revenue grew 1% year-over-year to $60.1 million, with strong margin expansion and adjusted operating income up 16.5%. SDC faced delivery reliability issues, but trailing 12-month revenue rose 5%. Focus remains on execution, deleveraging, and reinvestment in high-return segments.
Fiscal Year 2026
-
The company highlighted its strong recurring revenue base, disciplined growth through both organic initiatives and strategic acquisitions, and resilience amid recent market headwinds. With a focus on regulated markets and continuous operational improvement, it expects accelerating growth as clinical trial activity rebounds.
Fiscal Year 2025
-
Biopharmaceutical development and calibration solutions showed strong growth, with regional disparities in clinical genomics due to China headwinds. Cost reductions and reinvestments are supporting commercialization and operational improvements, while M&A and APAC expansion remain strategic priorities.